CVS, Cigna, and UnitedHealth inflated cancer and HIV drug prices, FTC says
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
FTC Says CVS, Cigna and UnitedHealth Abuse Middleman Role
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
FTC accuses CVS, Cigna, UnitedHealth of abusing middleman role, shares down
Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price ...
Modern Healthcare3d
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Honolulu Star-Advertiser2d
FTC: Pharmacy benefit managers inflated drug prices by $7.3B
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
MedCity News1d
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ ...